NCT05108519
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must be receiving any anti-VEGF-related regimen (e.g. Avastin/bevacizumab)
Exclusions: 
https://ClinicalTrials.gov/show/NCT05108519